ABVC BioPharma, Inc. (NASDAQ:ABVC) Short Interest Update

ABVC BioPharma, Inc. (NASDAQ:ABVC) saw a significant decrease in short interest in the month of January. As of January 30th, there was short interest totaling 250,987 shares, a decrease of 26.8% from the January 15th total of 342,721 shares. Approximately 1.2% of the shares of the company are short sold. Based on an average daily volume of 51,369 shares, the short-interest ratio is presently 4.9 days. Based on an average daily volume of 51,369 shares, the short-interest ratio is presently 4.9 days. Approximately 1.2% of the shares of the company are short sold.

ABVC BioPharma Stock Performance

ABVC stock opened at $1.67 on Friday. ABVC BioPharma has a 1 year low of $0.41 and a 1 year high of $5.48. The stock has a market capitalization of $42.45 million, a price-to-earnings ratio of -8.35 and a beta of 0.21. The stock’s fifty day moving average is $2.08 and its two-hundred day moving average is $2.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Millennium Management LLC acquired a new stake in shares of ABVC BioPharma in the third quarter valued at approximately $60,000. Citadel Advisors LLC bought a new position in ABVC BioPharma in the 3rd quarter worth approximately $48,000. Finally, Geode Capital Management LLC increased its position in ABVC BioPharma by 7.7% in the 4th quarter. Geode Capital Management LLC now owns 202,365 shares of the company’s stock valued at $431,000 after acquiring an additional 14,553 shares during the period. Institutional investors own 11.38% of the company’s stock.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ABVC BioPharma in a research report on Monday, December 29th. One analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ABVC BioPharma currently has an average rating of “Sell”.

About ABVC BioPharma

ABVC BioPharma is a clinical-stage biotechnology company focused on the discovery and development of novel vaccine and immunotherapy candidates for oncology and infectious diseases. The company leverages a proprietary peptide-based platform to identify and synthesize immunogenic epitopes, aiming to stimulate targeted immune responses against tumor-associated and pathogen-derived antigens.

The company’s pipeline includes active immunotherapy programs designed to address a range of cancer indications, along with vaccine candidates targeting bacterial pathogens.